Xin-Yun Zhang1, Hong-Jun Song1, Zhong-Ling Qiu2, Chen-Tian Shen1, Xiao-Yue Chen1, Zhen-Kui Sun1, Wei-Jun Wei1, Guo-Qiang Zhang1, Quan-Yong Luo3. 1. Department of Nuclear Medicine, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Jiao Tong University School of Medicine, 600# Yishan Road, 200233, Shanghai, China. 2. Department of Nuclear Medicine, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Jiao Tong University School of Medicine, 600# Yishan Road, 200233, Shanghai, China. qiuzhongling123@163.com. 3. Department of Nuclear Medicine, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Jiao Tong University School of Medicine, 600# Yishan Road, 200233, Shanghai, China. lqyn@sh163.net.
Abstract
PURPOSE: Papillary thyroid carcinoma (PTC) with pulmonary metastases is rare in children and adolescents. Unlike adults, limited data are available on children with this disease. Thus, this study evaluated the therapeutic efficacy and prognostic factors of individuals less than 21 years of age with pulmonary metastases from PTC. METHODS: Seventy-six children and adolescents with pulmonary metastases from PTC treated with 131I were retrospectively analyzed. Therapeutic efficacy was evaluated by changes in serum thyroglobulin (Tg) and chest computed tomography (CT). Factors predictive of progression-free survival and overall survival were measured by the Kaplan-Meier method. RESULTS: Among the 76 patients included in this study, 22.4% (17 of 76) were less than 15 years old and 65.8% (50 of 76) were female. Under the evaluation of stimulated serum Tg levels, RAI treatment were effective in 55.9% (38 of 68), stable in 26.5% (18 of 68) and ineffectvie in 17.6% (12 of 68) of patients. Changes on anatomical imaging suggested complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) in 8.5, 62.0, 15.5, and 14.1% of individuals, respectively. Univariate analysis showed that size and tumor doubling time of pulmonary metastases were independent factors affecting therapeutic efficacy. Extra-thyroidal extension, tumor diameter of pulmonary metastases and tumor doubling time were significant independent factors regarding progression-free survival rates, while only tumor doubling time and tumor diameter were significant risk factors associated with overall survival rate. CONCLUSIONS: Radioactive iodine therapy is an effective treatment for children and adolescents with pulmonary metastases from PTC. Extra-thyroid extension was associated with disease progression while did not show significant influence on overall survival. Tumor doubling time and tumor diameter were the main factors influencing both progression-free survival and overall survival.
PURPOSE:Papillary thyroid carcinoma (PTC) with pulmonary metastases is rare in children and adolescents. Unlike adults, limited data are available on children with this disease. Thus, this study evaluated the therapeutic efficacy and prognostic factors of individuals less than 21 years of age with pulmonary metastases from PTC. METHODS: Seventy-six children and adolescents with pulmonary metastases from PTC treated with 131I were retrospectively analyzed. Therapeutic efficacy was evaluated by changes in serum thyroglobulin (Tg) and chest computed tomography (CT). Factors predictive of progression-free survival and overall survival were measured by the Kaplan-Meier method. RESULTS: Among the 76 patients included in this study, 22.4% (17 of 76) were less than 15 years old and 65.8% (50 of 76) were female. Under the evaluation of stimulated serum Tg levels, RAI treatment were effective in 55.9% (38 of 68), stable in 26.5% (18 of 68) and ineffectvie in 17.6% (12 of 68) of patients. Changes on anatomical imaging suggested complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) in 8.5, 62.0, 15.5, and 14.1% of individuals, respectively. Univariate analysis showed that size and tumor doubling time of pulmonary metastases were independent factors affecting therapeutic efficacy. Extra-thyroidal extension, tumor diameter of pulmonary metastases and tumor doubling time were significant independent factors regarding progression-free survival rates, while only tumor doubling time and tumor diameter were significant risk factors associated with overall survival rate. CONCLUSIONS:Radioactive iodine therapy is an effective treatment for children and adolescents with pulmonary metastases from PTC. Extra-thyroid extension was associated with disease progression while did not show significant influence on overall survival. Tumor doubling time and tumor diameter were the main factors influencing both progression-free survival and overall survival.
Entities:
Keywords:
Children and adolescents; Papillary thyroid carcinoma; Pulmonary metastases; Radioactive iodine therapy; Tumor doubling time
Authors: C A Welch Dinauer; R M Tuttle; D K Robie; D R McClellan; R L Svec; C Adair; G L Francis Journal: Clin Endocrinol (Oxf) Date: 1998-11 Impact factor: 3.478
Authors: Sadana Balachandar; Michael La Quaglia; R Michael Tuttle; Glenn Heller; Ronald A Ghossein; Charles A Sklar Journal: Thyroid Date: 2016-02 Impact factor: 6.568
Authors: Theresa H M Keegan; Raymon H Grogan; Helen M Parsons; Li Tao; Michael G White; Kenan Onel; Pamela L Horn-Ross Journal: Thyroid Date: 2015-04-20 Impact factor: 6.568
Authors: Seo Young Sohn; Hye In Kim; Young Nam Kim; Tae Hyuk Kim; Sun Wook Kim; Jae Hoon Chung Journal: Clin Endocrinol (Oxf) Date: 2017-10-27 Impact factor: 3.478
Authors: Marloes Nies; Rena Vassilopoulou-Sellin; Roland L Bassett; Sireesha Yedururi; Mark E Zafereo; Maria E Cabanillas; Steven I Sherman; Thera P Links; Steven G Waguespack Journal: J Clin Endocrinol Metab Date: 2021-03-25 Impact factor: 5.958